key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with Grifols’ human albumin solution, Albutein, combined with intravenous immunoglobulin (IVIG).
Business Questions:
How successful do KOLs think that p38 MAP kinase alpha inhibition could prove to be as an approach for treating AD?
Do the results from the Phase IIa study with neflamapimod confirm its potential activity as a treatment for AD?
How important will the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy?
Do KOLs think that Elayta’s mechanism of action is compatible with it having a neuroprotective role in patients with AD?
Which types of patient are most likely to benefit from treatment with Elayta?
How do KOLs perceive plasma exchange as a method for reducing the beta-amyloid load in the brains of patients with AD?
Category: Healthcare Market Research
Aarkstore Enterprise
+91 9987295242 | [email protected] | aarkstore.com
The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response.
Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab.
Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments:Type of target disease indicationBone cancerColorectal cancerGynecological cancerNon-small cell lung cancerRenal cell carcinomaOther cancers Type of neoantigensPersonalized neoantigensOff-the-shelf neoantigens Type of immunotherapyDendritic cell vaccinesDNA / RNA-based vaccinesProtein / peptide-based vaccinesTIL-based therapies Route of administrationIntradermalIntravenousSubcutaneousOther routes Key geographical regionsNorth AmericaEuropeRest of the World The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy.
Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes.
The report includes detailed transcripts of discussions held with the following experts:Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)Ella Sorani (Vice President Research and Development, BioLineRx)Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM) The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain: Bavarian NordicGenocea BiosciencesPress Release: Variation 3 (Format 4) GradalisImmunicumImmunovative TherapiesIovance BiotherapeuticsMedigeneNeon TherapeuticsPrecision BiologicsVaxon Biotech Table of Contents Preface 2.
